Methods for administering specific VMAT2 inhibitors

JP7828390B2Active Publication Date: 2026-03-11NEUROCRINE BIOSCIENCES INC
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Filing Date
2024-06-07
Publication Date
2026-03-11

AI Technical Summary

Technical Problem

There is an unmet need for treatment of neurological and psychiatric disorders, particularly for patients using CYP2D6 inhibitors, where current methods struggle to effectively manage pharmacokinetic changes associated with VMAT2 inhibitors.

Method used

A method is provided to ensure that VMAT2 inhibitors effectively maintain therapeutic efficacy in the presence of CYP2D6 inhibitors by adjusting the dosage and administration sequence of VMAT2 inhibitors, including adjusting the dosage and administration of VMAT2 inhibitors before or after starting or continuing CYP2D6 inhibitor treatment.

Benefits of technology

This study achieved efficient administration of VMAT2 inhibitors in the presence of CYP2D6 inhibitors, reduced drug exposure-related adverse reactions, and ensured the stability and safety of therapeutic effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007828390000011
    Figure 0007828390000011
  • Figure 0007828390000012
    Figure 0007828390000012
  • Figure 0007828390000001
    Figure 0007828390000001
Patent Text Reader

Abstract

To provide methods for administration of certain VMAT2 inhibitors.SOLUTION: Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor selected from valbenazine and (+)-α-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol and pharmaceutically acceptable salts and / or isotopic variants thereof to a patient in need thereof, where a strong cytochrome P450 2D6 (CYP2D6) inhibitor is also being administered to the patient.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art